"Interleukin-23" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-23 is comprised of a unique 19 kDa subunit and 40 kDa subunit that is shared with INTERLEUKIN-12. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells
| Descriptor ID |
D053759
|
| MeSH Number(s) |
D12.644.276.374.465.759 D12.776.467.374.465.759 D23.529.374.465.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-23".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-23".
This graph shows the total number of publications written about "Interleukin-23" by people in this website by year, and whether "Interleukin-23" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 3 | 3 | 6 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 1 | 3 | 4 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 2 | 2 | 4 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 2 | 5 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 2 | 2 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-23" by people in Profiles.
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
-
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study. Lancet Rheumatol. 2023 Apr; 5(4):e200-e207.
-
Anti-IL 23 biologics for the treatment of plaque psoriasis. Expert Opin Biol Ther. 2022 12; 22(12):1489-1502.
-
Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling. Immunity. 2022 09 13; 55(9):1663-1679.e6.
-
IL-23 Monoclonal Antibodies for IBD: So Many, So Different? J Crohns Colitis. 2022 May 11; 16(Supplement_2):ii42-ii53.
-
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2022 06; 149(6):2010-2020.e8.
-
Skin-resident innate lymphoid cells converge on a pathogenic effector state. Nature. 2021 04; 592(7852):128-132.
-
The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Mar; 84(3):676-690.
-
MAIT cells are imprinted by the microbiota in early life and promote tissue repair. Science. 2019 10 25; 366(6464).
-
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152.